Replimune Group Inc.

With 22 novel agents approved in the first six months of 2025, the US FDA is already behind its average approval count for the first half of the year, and the user fee calendar for the second half doe

July is inextricably linked with Independence Day in the US, but the calendar of applications that are up for Food and Drug Administration actions in July 2025 is notable for the number of novel candi

The regenerative medicine sector continues to seek increased contact with the US Food and Drug Administration, even as the architects of the Center for Biologics Evaluation and Research review structu

Private investment in public equity (PIPE) transactions continue to be an important means of fundraising for publicly traded biopharmaceutical companies while the financial markets continue to recover